Home > Boards > US OTC > Medical - Drugs > Spotlight Innovation Inc. (STLT)

Convertible debt fear is one issue, they have

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Ecomike Member Profile
Member Level 
Followed By 431
Posts 49,213
Boards Moderated 11
Alias Born 10/05/09
160x600 placeholder
Ecomike Member Level  Monday, 12/24/18 11:07:47 AM
Re: PennyStockTrader2 post# 1972
Post # of 1992 
Convertible debt fear is one issue, they have a lot of it, but the two founder CEOs own 66% of the OS, and the current CEO is the one that has been funding it, so he has little reason it seems to PR/pump the stock with fake news.

Recent lay offs of officers is a concern, very late now on the last SEC financial is a big concern.

The Venodol has already been marketed and is sold on line and at stores by Walmart and Amazon. They have patents. The Celtic Biotech company they bought was valued at 3 Million dollars.

With the stock price at .01 and only 30 Mil shares issued, the market cap is now $300,000 or 10% of what they paid for just one company they bought. One of the operations won a $300,000 R&D grant just about 6 months ago. This was at $2, 2 years ago, and .25 earlier this year. Float is just under 10 mil shares, and tightly held as the volume has died down here, not even any tax loss selling now.

And SEC filling, financials would rally it.

Happy Holidays!



All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist